In our preliminary experimentation to determine the optimal FGF21 concentration, guided by prior research on the therapeutic application of FGF21 in CNS disorders [20, 35, 36], we administered three distinct doses (0.75 mg/kg, 1.5 mg/kg, and 3 mg/kg) of FGF21 to assess their efficacy in ameliorating cerebral edema and neurological impairment post-SAH. This evidence concerns the gene FGF21 and central nervous system disorder.